A glimpse of the future. new directions in the treatment of colorectal cancer.
This paper overviews new directions in colorectal cancer therapy, focusing on adjuvant therapy, new cytotoxic agents and novel approaches. Reduced mortality with adjuvant therapy is mainly achieved in resectable colorectal cancer, using regimens of 5-fluorouracil (5-FU) plus leucovorin, 5-FU plus levamisole and 5-FU plus radiation. Not all patients are suitable for adjuvant therapy, and a better definition of prognostic factors will improve selection of patients for therapy. Several thymidylate synthase inhibitors are in development, including 'Tomudex' (raltitrexed, previously known as ZD1694), which has reached phase III studies, LY 231514, AG 331, AG 337, BW 1843 U89 and ZD 9331. Topoisomerase I inhibitors (e.g. CPT II, topotecan), ethynyluracil, oxaliplatin and 5-FU prodrugs are also promising therapeutic agents. Novel approaches include angiogenesis inhibitors, drugs which can stimulate apoptosis, generation of cytotoxic drugs from non-toxic prodrugs at tumour sites and conjugation of anti-tumour agents to polymeric carriers. Various modalities of specific and non-specific immunotherapy are also under research. These advancements promise improvements in the prognosis of colorectal cancer patients.
Van Cutsem
E
E
Department of Internal Medicine, University Hospital Gasthuisberg, Leuven, Belgium.
D000970:Antineoplastic Agents / Q000627:therapeutic use; D017024:Chemotherapy, Adjuvant / Q000639:trends; D015179:Colorectal Neoplasms / Q000188:drug therapy* / Q000628:therapy; D006801:Humans; D007167:Immunotherapy / Q000639:trends; D013940:Thymidylate Synthase / Q000037:antagonists & inhibitors; D059004:Topoisomerase I Inhibitors
D000970:Antineoplastic Agents; D059004:Topoisomerase I Inhibitors; D013940:Thymidylate Synthase